RecruitingNCT07166445

Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT


Sponsor

Peking University First Hospital

Enrollment

1,000 participants

Start Date

Sep 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims to develop and validate a contrast-enhanced CT-based deep-learning model for automatic and accurate preoperative discrimination between T1-T2 and T3 renal cell carcinoma. By quantifying the model's diagnostic performance on an independent test set-using AUC, sensitivity, specificity, positive/negative predictive values, and decision-curve analysis-we will establish a decision-support tool that can be seamlessly integrated into clinical PACS, thereby reducing staging errors, refining surgical planning, and improving patient outcomes.


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Inclusion Criteria4

  • Histopathologically confirmed renal cell carcinoma on postoperative specimen.
  • Preoperative contrast-enhanced CT performed at our institution with slice thickness ≤ 1 mm and complete DICOM datasets.
  • Postoperative pathologic staging clearly defined as pT1a-T2b or pT3a.
  • CT image quality deemed adequate for analysis.

Exclusion Criteria1

  • \. Pathologic subtype other than RCC. 2. Images with severe artifacts.

Interventions

OTHERNone intervention

this study is retrospective based on the CT images, which dose include any intervention.


Locations(1)

Peking University First Hospital, Beijing,

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07166445


Related Trials